FINCH THERAPEUTICS GROUP

YTD

ALL

Why Robinhood?

You can watch FNCH and buy or sell other stocks, ETFs, and their options commission-free!

About FNCH

Finch Therapeutics Group, Inc. engages in the development of microbiome drugs. Its platform includes Human-First Discovery that enables reverse translation from clinical data to engineer the composition of the microbiome based on disease-modifying mechanisms.

CEO

Matthew P. Blischak

CEOMatthew P. Blischak

Employees

Employees18

Headquarters

Somerville, Massachusetts

HeadquartersSomerville, Massachusetts

Founded

2014

Founded2014

Employees

Employees18

FNCH Key Statistics

Market cap

638.40M

Market cap638.40M

Price-Earnings ratio

-2.53

Price-Earnings ratio-2.53

Dividend yield

—

Dividend yield—

Average volume

107.56K

Average volume107.56K

High today

$13.26

High today$13.26

Low today

$13.00

Low today$13.00

Open price

$13.26

Open price$13.26

Volume

200.00

Volume200.00

52 Week high

$13.26

52 Week high$13.26

52 Week low

$0.2505

52 Week low$0.2505

People also own

Based on the portfolios of people who own FNCH. This list is generated using Robinhood data, and it’s not a recommendation.

FINCH THERAPEUTICS GROUP

Why Robinhood?

Finch Therapeutics Group, Inc. engages in the development of microbiome drugs. Its platform includes Human-First Discovery that enables reverse translation from clinical data to engineer the composition of the microbiome based on disease-modifying mechanisms. Show more

FNCH Key Statistics

People also own

Finch Therapeutics Group, Inc. engages in the development of microbiome drugs. Its platform includes Human-First Discovery that enables reverse translation from clinical data to engineer the composition of the microbiome based on disease-modifying mechanisms.